Lanzelo
Mampiova ny paikady erantany ankehitriny ny valanaretina Covid-19 “variant sud-africain” na B1351 izay mahery vaika na dia miadana kokoa ny fiparitahany noho ilay karazany voalohany SARS-CoV-2. Olona 44 no voamarina fa mitondra ny soritraretina mifandraika amin’ny B1351 ao Londres, renivohitr’Angletera, izay nahitàna fanalefahana ireo fepetra mikasika ny fihibohana. Mampametra-panontaniana izany eo anatrehan’ireo rehetra efa vita vakisiny. Hahatohitra ny B1351 ve izy ireo satria ho an’ny ankamaroany dia vakisiny Oxford-AstraZenecca no nanindromana azy.
Raha eo anivon’ireo vakisiny nomen’ny OMS halalana dia voalaza fa ny Pfizer-BioNTech no vakisiny mandaitra indrindra entina miady amin’ny B1351. Manaraka an’io dia ny Moderna sy ny Johnson & Johnson izay voalaza fa lefilefy kokoa ny heriny eo anatrehan’ny B1351. Ny Oxford-AstraZeneca sy ny Spoutnik V indray dia voafaritra hatreto fa tsy ampy entina miady amin’ny B1351.
Anaty ny praograma Covax izay misy ny famatsiana manokana an’ireo firenena mahantra dia efa nahazo vakisiny AstraZeneca 600.000 ny Ghana ary 504.000 ny Côte d’Ivoire. Hanao ahoana koa izany ny fiatrehana ny B1351 raha sanatria tafiditra ao Ghana na Côte d’Ivoire?
Tsy mipetraka aloha eto ny fanontaniana ho an’i Madagasikara satria variana mitavozavoza ny fitondrana, ny filoha mbola mahavita miala sasatra no sady mandainga ihany hoe ampy ny fanafody.
Rohy
https://www.theguardian.com/world/2021/apr/12/surge-testing-deployed-in-south-london-as-south-african-covid-variant-cases-rise
https://www.standard.co.uk/news/london/london-soho-lockdown-shops-pubs-dancing-b929341.html
https://www.reuters.com/article/us-health-coronavirus-pfizer-idUSKBN2BO59L
https://www.cidrap.umn.edu/news-perspective/2021/03/covid-19-antibodies-appear-ward-b117-better-b1351
https://www.bmj.com/content/372/bmj.n597
https://www.cidrap.umn.edu/news-perspective/2021/03/astrazeneca-vaccine-doesnt-prevent-b1351-covid-early-trial
https://www.news-medical.net/news/20210406/South-Africa-SARS-CoV-2-variant-B1351-easily-escapes-Sputnik-vaccine.aspx
